Introduction
Meniere’s disease(MD) is an idiopathic inner ear disorder characterized by episodic attacks of vertigo, fluctuating hearing loss, tinnitus, and aural fullness. MD exhibits a relapsing-remitting pattern, with episodic attacks terminated by periods of restitution to normal auditory and vestibular function. Additionally, auditory and vestibular function decline over time.Although the pathophysiologic mechanism of MD is well accepted, the underlying causes remains uncertain1. MD treatment is still objective of controversies in literature and it must be first based on a trustable diagnosis, as recommended by guidelines and classification of the AAO-HSN published in 19952and reviewed by the Equilibrium Committee in 20153. MD has a considerable negative effect on patient’s quality of life so current therapies are directed to prevent or reduce the frequency and severity of vertigo crises4. Intratympanic injection of gentamicin(ITG) is considered the treatment of choice in patients with refractory disease1,4. However due to its possible hearing side effects there is still no general consensus on dose and timing of ITG4.
The aim of our study is to evaluate the effectiveness of intratympanic injection of gentamicin on vertigo control with close doses and its hearing effects.